亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Chemotherapy Dose Reductions and Dose Delays Due to Thrombocytopenia

化疗 医学 化疗方案 内科学
作者
Gautham Prakash,Kelsey Pandrangi,Ranya Khateeb,Shivi Jain
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 11248-11249
标识
DOI:10.1182/blood-2022-171193
摘要

Background: Chemotherapy-induced thrombocytopenia (CIT) is a challenging clinical scenario. A recent study of 15,521 patients showed that 13% of patients with solid tumors had thrombocytopenia within 3 months (Shaw, Eur J Haematol. 2021).Unfortunately, there are no guidelines for the management of CIT. Therefore, clinicians use strategies such dose reduction (DR) and/or dose delays (DD) to reduce the bleeding risk(Kuter, Haematologica. 2022). Although the incidence of CIT in various types of cancers and chemotherapeutic agents is known, studies showing an association between DR or DD and duration of CIT are lacking. It is known that DR and DD can increase mortality(Havrilesky, Crit Reviews in Onc/Hematology. 2015; Liutkauskiene, BMC Cancer. 2018). The association of cirrhosis and duration of thrombocytopenia in patients with CIT is also not well described. Therefore, we conducted a retrospective analysis to study the association between duration of thrombocytopenia and dose delays and reduction in patients with CIT. Methods: This study was approved by the Institutional Review Board. A retrospective analysis was performed using the electronic medical record (EMR) for adult patients who received chemotherapy for breast, GI, GU, and lung cancer from January 1st, 2016, to December 31st, 2020, at Rush University Cancer Center. Adult patients who developed thrombocytopenia during treatment (platelet count < 100 × 109 /L) were included in the study. Patients with thrombocytopenia preceding the initiation of chemotherapy were excluded. One hundred thirty-five patients met the study inclusion criteria. EMR were reviewed to collect data on DR and DD that had been clearly attributed to chemotherapy by the treating oncologist's documentation. Data for age at first thrombocytopenia (following treatment initiation), total duration of thrombocytopenia, presence of cirrhosis, and presence of liver metastasis was collected. Pearson's chi-square test and logistic regression were used to test the associations between duration of thrombocytopenia (grouped as <14 days or ≥ 14 days) and the proportion of patients who experienced at least one DR or DD. We similarly tested the association between thrombocytopenia duration and cirrhosis or liver metastasis. Results: First, we analyzed the association between DR, DD, and duration of thrombocytopenia. There was no statistically significant association between duration of thrombocytopenia and DR. However, we found that patients with DD had 4.1 times the odds of having increased duration of thrombocytopenia (≥ 14 days) compared to the patients without DD (OR = 4.1, 95% CI = 2.0 - 8.5, P-value = 0.0001). Then, we studied the association between DD and duration of thrombocytopenia in patients with cirrhosis or liver metastasis. We found that in this subset patients with DD had 3.9 times the odds of having thrombocytopenia duration ≥ 14 days compared to the patients without DD (OR = 3.9, 95% CI = 1.4 - 10.8, P-value = 0.008). We then looked at the association of having cirrhosis and liver metastasis on duration of thrombocytopenia. We found that there was no statistically significant association between presence of liver metastasis and duration of thrombocytopenia. However, patients with cirrhosis had 3.5 times the odds of having thrombocytopenia duration ≥14 days compared to patients without cirrhosis (OR = 3.5, 95% CI = 1.1 - 11.3, P-value = 0.03). Discussion: Our study shows that in patients with CIT, duration of thrombocytopenia impacts the risk of DD, especially in patients with either cirrhosis or liver metastasis. The finding of interest is that patients with cirrhosis have a 4-fold increased risk of developing longer duration of thrombocytopenia, which can lead to dose delays. This raises the question of whether patients with cirrhosis should be supported by thrombopoietin receptor agonists to treat the thrombocytopenia and prevent treatment delays. Thrombopoietin (TPO) receptor agonists such as Romiplostim are showing increasing promise in the treatment of CIT, and there are currently multiple active phase III trials underway with dose-reductions and dose-delays as clinical endpoints. Further research is needed to identify risk factors that can predict the development of CIT and to identify evidence-based platelet thresholds for TPO agonist usage in CIT patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CipherSage应助发疯的科研采纳,获得10
1秒前
CipherSage应助八合一采纳,获得10
3秒前
强健的迎波完成签到,获得积分10
5秒前
失眠呆呆鱼完成签到 ,获得积分10
6秒前
17秒前
20秒前
20秒前
20秒前
dong应助科研通管家采纳,获得10
21秒前
dong应助科研通管家采纳,获得10
21秒前
八合一发布了新的文献求助10
22秒前
外星人发布了新的文献求助10
25秒前
josephina发布了新的文献求助10
26秒前
CAOHOU给SimonLee的求助进行了留言
29秒前
程宇应助吴DrYDYY采纳,获得20
47秒前
冷酷完成签到,获得积分10
50秒前
wanci应助远方采纳,获得10
50秒前
53秒前
哈哈哈哈哈哈哈完成签到,获得积分10
53秒前
oleskarabach完成签到,获得积分20
54秒前
佛系完成签到 ,获得积分10
54秒前
李治稳发布了新的文献求助10
58秒前
子咸发布了新的文献求助10
1分钟前
oleskarabach发布了新的文献求助10
1分钟前
程风破浪发布了新的文献求助50
1分钟前
yangl完成签到 ,获得积分10
1分钟前
josephina完成签到,获得积分10
1分钟前
田様应助清脆的绮梅采纳,获得10
1分钟前
查文献的大猫完成签到,获得积分10
1分钟前
1分钟前
sola完成签到 ,获得积分10
1分钟前
伯爵的猫完成签到,获得积分10
1分钟前
勤恳的断秋完成签到 ,获得积分10
1分钟前
程宇给cccccl的求助进行了留言
1分钟前
程风破浪完成签到,获得积分10
1分钟前
不羁完成签到 ,获得积分10
1分钟前
he完成签到,获得积分10
1分钟前
jueshadi发布了新的文献求助10
2分钟前
丁静完成签到 ,获得积分10
2分钟前
蛋黄啵啵完成签到 ,获得积分10
2分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Social Research Methods (4th Edition) by Maggie Walter (2019) 1030
A new approach to the extrapolation of accelerated life test data 1000
Indomethacinのヒトにおける経皮吸収 400
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 370
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3994955
求助须知:如何正确求助?哪些是违规求助? 3535071
关于积分的说明 11267066
捐赠科研通 3274842
什么是DOI,文献DOI怎么找? 1806483
邀请新用户注册赠送积分活动 883335
科研通“疑难数据库(出版商)”最低求助积分说明 809762